¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2023 ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-10-14

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2023 ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-10-14
±³À°ÀÏÀÚ : 2023-10-14
±³À°Àå¼Ò : °æÁÖ È­¹éÄÁº¥¼Ç¼¾ÅÍ

±³À°ÁÖÁ¦ : 2023 ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö

ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¼Ò¾Æ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸

´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581

À̸ÞÀÏ : hematology@kams.or.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú

Âü¼®¿¹»óÀÎ : 50¸í
Èñ¸ÁÆòÁ¡ : 4Á¡

Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 4 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 0¿ø  

ºñ°í


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 10¿ù 14ÀÏ 101 10:00~10:30 MRD(minimal residual disease) diagnostic technique in adult ALL(acute lymphoblastic leukemia)                          ÀÌÁö¼ö(¼­¿ïÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 10:30~11:00 MRD(minimal residual disease)-based treatment approach: real world experience Á¤Çظ²(¿¬¼¼ÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 11:10~11:40 Recent advances in immunotherapy & CAR-T in ALL(acute lymphoblastic leukemia) À±ÀçÈ£(°¡Å縯ÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 11:40~12:10 Optimal sequencing treatment for relapsed ALL(acute lymphoblastic leukemia ) ÀÌÁöÇö(µ¿¾ÆÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 13:10~13:40 "Clinical impacts of the concomitant use of L-asparaginase and total parenteral nutrition in ALL(acute lymphoblastic leukemia)  patients " °í¹Î¿À(¼­¿ï´ë¾à)

±³À°½Ã°£ 10¿ù 14ÀÏ 101 13:40~14:10 Recent update of antibody-based chemotherapy in newly diagnosed adult ALL(acute lymphoblastic leukemia) ¹éµ¿¿ø(°æºÏÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 14:10~14:40 CNS(central nervous system) Relapse in adult ALL(acute lymphoblastic leukemia) patients ÀÌÁ¾Çõ(°¡Å縯ÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 15:00~15:30 "Phase II trial of Rituximab preconditioning for relapsed/refractory B-cell ALL treated with blinatumomab (RICOBAL) " º¯ÀÚ¹Î(¼­¿ïÀÇ´ë )

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2023 ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-10-14""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Çѱ¹À¯¹æ¾ÏÇÐȸ 2023 Ãß°èÇмú´ëȸ : 2023-10-14
´ÙÀ½±Û Á¦19ȸ Çѱ¹ÀÓ»ó½Ã°¢Àü±â»ý¸®ÇÐȸ Á¤±â½ÉÆ÷Áö¾ö : 2023-10-14
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20559 °æ±â Á¦34Â÷ Áß¾Ó´ëÇб³ ºñ´¢ÀÇÇаú ¿öÅ©¼¥ : 2024-06-01 0 55 2024-04-29
20558 ±¤ÁÖ Á¦2ȸ ´ëÇѺñ¸¸ÇÐȸ È£³²Áöȸ Çмú´ëȸ : 2024-06-01 0 64 2024-04-29
20557 ÀÎõ 2024³â ±èÆ÷½ÃÀÇ»çȸ Ãá°èÇмú´ëȸ : 2024-06-01 0 48 2024-04-29
20556 ¼­¿ï 2024 ´ëÇÑ¿ì¿ïÇൿ½Å°æÇבּ¸È¸ Ãá°èÇмú´ëȸ : 2024-06-01 0 42 2024-04-29
20555 ¼­¿ï ´ëÇѽÉÀåÇ÷°üÈäºÎ¿Ü°úÇÐȸ Á¦38Â÷ Ãá°èÅëÇÕÇмú´ëȸ ¹× ¿¬¼ö±³À° (2ÀÏÂ÷) : 2024-06-01 0 34 2024-04-29
20554 ¼­¿ï Á¦ 14Â÷ ´ëÇѸð¹ßÀ̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ(1ÀÏÂ÷) : 2024-06-01 0 37 2024-04-29
20553 ¼­¿ï 2024³â ´ëÇѼҾư¨¿°ÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-31 0 57 2024-04-29
20552 Àü³² ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ È£³²Áöȸ - Á¦297Â÷ ¿ù·ÊÁý´ãȸ : 2024-05-31 0 67 2024-04-29
20551 ¼­¿ï (¿Â¶óÀÎ) 2024 Çѱ¹Á¤½ÅºÐ¼®ÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-31 0 94 2024-04-29
20550 ºÎ»ê Á¦ 169Â÷ ºÎ»êÁö¹æ³²¼º°úÇÐȸ Çмú´ëȸ : 2024-05-31 0 47 2024-04-29
20549 ¼­¿ï ´ëÇѼҾư¨¿°ÇÐȸ Á¦26ȸ ¿¬¼ö°­Á : 2024-05-30 0 46 2024-04-29
20548 °­¿ø 2024³â ¿øÁÖ½ÃÀÇ»çȸ 2Â÷ ¿¬¼ö°­ÁÂ_ÃÖ±Ù ÀÇÇÐÁö°ß : 2024-05-28 0 57 2024-04-29
20547 °æ±â Á¦4ȸ ´ëÇÑ¿Ü°úÇÐȸ ¿Ü°ú³»½Ã°æ ¿¬¼ö°­Á : 2024-05-26 0 62 2024-04-29
20546 ¼­¿ï ´ëÇѺñ´¢ÃÊÀ½ÆÄÇÐȸ Á¦17Â÷ Çмú´ëȸ : 2024-05-26 0 35 2024-04-29
20545 °æºÏ 2024³âµµ °æ»óºÏµµÀÇ»çȸ Á¾ÇÕÇмú´ëȸ(2ÀÏÂ÷) : 2024-05-26 0 71 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷